Huaren Pharmaceutical Co., Ltd.

300110

CNE100000SW1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.7 ^CNY	+2.49%		+10.45%	-12.32%

Apr. 25	Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
Apr. 24	Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Huaren Pharmaceutical Co., Ltd.(XSEC:300110) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Huaren Pharmaceutical Co., Ltd.

Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 24	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Huaren Pharma's Unit Gets Nod for Medical Device	Apr. 04	MT
Huaren Pharma's Unit Gets Nod to Add Specifications to Antibiotic Product	Feb. 22	MT
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Huaren Pharmaceutical Co., Ltd.(XSEC:300110) added to S&P Global BMI Index	23-09-18	CI
Huaren Pharmaceutical Co., Ltd. Announces Director Appointments	23-09-13	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 12 July 2023	23-07-03	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-19	CI
Huaren Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022	23-03-27	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Huaren Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.339851 billion in funding from Xi'an Qujiang Tianshou Great Health Investment Partnership Enterprise ( Limited Partnership)	23-03-22	CI
Huaren Pharma Appoints Executive President	22-12-30	MT
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-20	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Huaren Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022	22-06-13	CI
Huaren Pharmaceutical Co., Ltd. Approves Board Appointments	22-04-22	CI
Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2021	22-04-22	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-22	CI
Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021	22-03-31	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-20	CI

Chart Huaren Pharmaceutical Co., Ltd.

Duration

Period

More charts

Huaren Pharmaceutical CO.,LTD is a China-based company principally engaged in the research, development, manufacture and distribution of non polyvinyl chloride (PVC) soft bag large volume preparations. The Company provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The Company distributes its products in domestic market, with Northeast China as its main market.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HUAREN PHARMACEUTICAL CO., LTD.	-12.32%	604M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.18B
OTSUKA HOLDINGS CO., LTD.	+24.05%	23.23B
SANDOZ GROUP AG	+15.11%	14.6B
CIPLA LIMITED	+12.33%	13.54B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.5B
ONO PHARMACEUTICAL CO., LTD.	-7.63%	6.79B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.31B